ACADIA Pharmaceuticals (ACAD) : The bears are holding on to their shorts in Accenture Plc with 7 more days remaining for them to cover their positions. The bearish positions have increased from 17,992,107 on Jul 29, 2016, to 18,966,307, on August 15, 2016. Daily, 2,564,405 shares are traded, which shows the high interest of the traders in the stock. The net addition of short open interest is 974,200 shares, which is an increase of just 5.4%. The total short interest of 16.8% of the float indicates that there arent many bears on this stock at the current prices. The short interest information was released on Wednesday Aug 24th after the market close.
ACADIA Pharmaceuticals (NASDAQ:ACAD): The stock opened at $34.36 on Wednesday but the bulls could not build on the opening and the stock topped out at $35.34 for the day. The stock traded down to $32.33 during the day, due to lack of any buying support eventually closed down at $32.46 with a loss of -5.53% for the day. The stock had closed at $34.36 on the previous day. The total traded volume was 2,340,171 shares.
In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the 0 of Acadia Pharmaceuticals Inc, Harrigan Edmund had purchased shares worth of $32,970 in a transaction dated on August 16, 2016. A total of 1,000 shares were purchased at a price of $32.97 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.